Last reviewed · How we verify
GSK drug
At a glance
| Generic name | GSK drug |
|---|---|
| Also known as | BIIB074 and CNV1014802 |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Administration site pain
- Headache
- Fatigue
- Nausea
- Myalgia
- Administration site erythema
- Administration site swelling
- Arthralgia
- Administration site induration
- Nasopharyngitis
- PAIN
- Pyrexia
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection (PHASE1, PHASE2)
- Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart (PHASE4)
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals (PHASE1, PHASE2)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery (PHASE1)
- Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK drug CI brief — competitive landscape report
- GSK drug updates RSS · CI watch RSS
- Biogen portfolio CI